RxDoctor Payments Data

Tammi Cawthra, APRN

Family · Benkelman, NENPI 1972089357

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $213, more than ten times the $14 reported in 2021.

$361in general payments, 2019–2025

Across 10 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$84
  • Johnson & Johnson$65
  • Janssen Scientific Affairs, LLC$51
  • Novartis$49
  • AbbVie$43
  • Novo Nordisk$34
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$361 in reported general payments places this provider in the 55th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,872
Medicare patients
34
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$16,550
EliquisApixaban14$11,193
XareltoRivaroxaban17$9,788
MyrbetriqMirabegron13$7,808
Fentanyl36$4,878
Atorvastatin Calcium204$2,288
Levothyroxine Sodium193$1,652
Tamsulosin Hcl119$1,592
Omeprazole198$1,544
Lisinopril237$1,296
ValacyclovirValacyclovir Hcl17$1,276
Albuterol Sulfate HfaAlbuterol Sulfate34$1,260
Potassium Chloride81$1,159
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$1,070
Gabapentin71$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$16,55016 claims
Johnson & JohnsonXarelto$65$9,78817 claims
AbbVieSynthroid$43$66513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 809 family providers in Nebraska.

Other family in Benkelman

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →